MedTrace Logo

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

NCT01699217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2025-04-18

No results posted yet for this study

Summary

The GIMEMA CML Working Party promotes a multicentre, observational, prospective study of CML patients treated frontline with NIL. Patients will be followed for 5 years. This study will help the definition of guidelines for the treatment of CML patients in early CP.

Conditions

  • Chronic Phase Philadelphia Positive
  • BCR-ABL Positive
  • Chronic Myeloid Leukaemia

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Gianantonio Rosti, Pr. · Department of Hematology and Oncological Sciences, S.Orsola-Malpighi Hospital, University of Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-21
Primary Completion
2017-12-16
Completion
2023-12-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699217 on ClinicalTrials.gov